GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » China Biotech Services Holdings Ltd (HKSE:08037) » Definitions » Net Change in Cash

China Biotech Services Holdings (HKSE:08037) Net Change in Cash : HK$0.0 Mil (TTM As of Jun. 2024)


View and export this data going back to 2004. Start your Free Trial

What is China Biotech Services Holdings Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

China Biotech Services Holdings's Net Change in Cash for the three months ended in Jun. 2024 was HK$0.0 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.0 Mil.

China Biotech Services Holdings Net Change in Cash Historical Data

The historical data trend for China Biotech Services Holdings's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Biotech Services Holdings Net Change in Cash Chart

China Biotech Services Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -108.96 339.02 -233.99 -57.78 -20.68

China Biotech Services Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

China Biotech Services Holdings Net Change in Cash Calculation

China Biotech Services Holdings's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=195.193+-67.531+-146.167+-2.178
=-20.7

China Biotech Services Holdings's Net Change in Cash for the quarter that ended in Jun. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=0+0+0+0
=0.0

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Biotech Services Holdings Net Change in Cash Related Terms

Thank you for viewing the detailed overview of China Biotech Services Holdings's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

China Biotech Services Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » China Biotech Services Holdings Ltd (HKSE:08037) » Definitions » Net Change in Cash
Comparable Companies
HKSE:02427 HKSE:08225 HKSE:08247 HKSE:00928 HKSE:09960 HKSE:06667 TMO DHR XSWX:LONN A IDXX IQV SHSE:603259 MTD WAT NTRA LH DGX ICLR ILMN
Traded in Other Exchanges
N/A
Address
255-257 Gloucester Roaad, Suites 1904-05A, 19th Floor, Sino Plaza, Causeway Bay, Hong Kong, HKG
Website
http://www.cbshhk.com
China Biotech Services Holdings Ltd is an investment holding company. It operates through six segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Securities, Insurance brokerage, BNCT and Others. It derives prime revenue from the Medical and health related services segment which involves the provision of medical laboratory testing and health check services. The group has a business presence in Hong Kong and the PRC, of which key revenue is generated from Hong Kong.
Executives
Guoyuan International Holdings Limited 2201 Interest of corporation controlled by you
Guoyuan Securities Co., Ltd. 2201 Interest of corporation controlled by you
Guoyuan Securities Investment (hong Kong) Limited 2101 Beneficial owner
Genius Earn Limited 2201 Interest of corporation controlled by you
Genius Lead Limited 2101 Beneficial owner
Liu Xiaolin 2101 Beneficial owner
Richlane Ventures Limited 2101 Beneficial owner
Ko Chun Shun, Johnson 2201 Interest of corporation controlled by you

China Biotech Services Holdings Headlines

No Headlines